University of North Carolina, Lineberger Comprehensive Cancer Center | Strategic Alliance Partners

May 08, 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

April 25, 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer.

March 27, 2017

Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.

March 27, 2017

Jared Weiss, MD, offers his expert insight into the actual impact of the immunotherapy advances in lung cancer.

March 20, 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

March 08, 2017

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

February 28, 2017

Carey Anders, MD, discusses available and emerging treatment options for patients with breast cancer that has metastasized to the brain.

February 04, 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses next steps for immunotherapy agents in the treatment of patients with head and neck cancer.

February 01, 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

January 30, 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

December 02, 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the ongoing progress with agents in development for the potential treatment of patients with HER2-positive breast cancer.

November 23, 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses how she has seen various agents impact quality of life (QOL) when used to treat patients with breast cancer.

November 17, 2016

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.

November 15, 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

October 28, 2016

Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses refinements needed in surgery for the treatment of patients with metastatic breast cancer during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

October 22, 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.

October 20, 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses why brain metastases is such a prominent issue in patients with breast cancer in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

October 19, 2016

Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses the evolving role of surgery in the treatment of patients with metastatic breast cancer.

August 12, 2016

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

June 27, 2016

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.